Private Market View

Zhongke Kangyuan Biotechnology

Tangshan, China · Founded 2018 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Wuxi Capital, SDIC Juli Investment.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Zhongke Kangyuan Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Zhongke Kangyuan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Zhongke Kangyuan Biotechnology

Manufacturer of biological conversion technologies intended for agricultural and environmental applications. The company offers microbial fermentation, enzyme engineering, biomass pretreatment, and nutrient optimization processes, enabling the agriculture and animal husbandry market to improve feed efficiency, reduce dependence on conventional grain resources, enhance sustainability through waste utilization, lower production costs, support healthier livestock growth, and achieve scalable ecological benefits while maintaining consistent performance across diverse production environments.

Sector
Healthcare
HQ
Tangshan, China
Founded
2018
Employees
58
Ownership
Privately Held (backing)
PA Mark — not yet priced

Zhongke Kangyuan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Zhongke Kangyuan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Zhongke Kangyuan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.